Park resigns from Isotechnika as ILJIN takes control
This article was originally published in Scrip
Daniel Park has resigned his position as chief business officer of Isotechnika Pharma, a biopharmaceutical company developing immunomodulating therapeutics, to avoid potential conflicts of interest that may arise as a result of his position as executive vice-president of ILJIN Life Science, which Mr Park has informed Isotechnika, intends to "increase its level of control within the company". Mr Park will remain on Isotechnika's board of directors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.